StockNews.com upgraded shares of XOMA (NASDAQ:XOMA – Free Report) from a sell rating to a hold rating in a report published on Wednesday.
A number of other research analysts have also issued reports on XOMA. Leerink Partnrs reiterated an outperform rating on shares of XOMA in a report on Monday, April 29th. HC Wainwright reissued a buy rating and issued a $74.00 price objective on shares of XOMA in a research note on Tuesday, July 9th. Finally, SVB Leerink assumed coverage on XOMA in a research report on Monday, April 29th. They set an outperform rating and a $40.00 target price for the company.
Get Our Latest Research Report on XOMA
XOMA Price Performance
Institutional Investors Weigh In On XOMA
Several large investors have recently modified their holdings of the company. BNP Paribas Financial Markets lifted its holdings in XOMA by 55.6% in the first quarter. BNP Paribas Financial Markets now owns 3,543 shares of the biotechnology company’s stock valued at $85,000 after buying an additional 1,266 shares during the period. Price T Rowe Associates Inc. MD bought a new position in shares of XOMA in the 1st quarter worth about $212,000. Rhumbline Advisers boosted its position in shares of XOMA by 16.0% during the 2nd quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock valued at $230,000 after purchasing an additional 1,334 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its stake in XOMA by 3.2% during the second quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock worth $1,484,000 after purchasing an additional 1,968 shares during the period. 95.92% of the stock is currently owned by institutional investors and hedge funds.
About XOMA
XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.
Featured Stories
- Five stocks we like better than XOMA
- What is a SEC Filing?
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- What Makes a Stock a Good Dividend Stock?
- MarketBeat Week in Review – 8/12 – 8/16
- Insider Trading – What You Need to Know
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.